Clinical Trials Browser

NCT04400695 2024-01-24

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Phase 3 Unknown

366 enrolled

Breast

Breast Neoplasms

NCT03664895 2023-12-04

Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)

Phase 3 Unknown

224 enrolled

Breast

Breast Cancer Invasive

NCT06152471 2023-11-30

ASF-BC

Phase 3 Unknown

100 enrolled

Breast

Breast Neoplasms, Diarrhea, Drug-Related Side Effects and Adverse Reactions

NCT03926091 2023-11-14

CLOVER

Phase 3 Unknown

2,172 enrolled

Breast

Breast Neoplasms

NCT05673629 2023-11-08

Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Phase 3 Unknown

552 enrolled

Breast

Breast Neoplasms

NCT04858529 2023-11-07

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Phase 3 Unknown

774 enrolled

Breast

Neoadjuvant Therapies for HER2+ Breast Cancer

NCT05144867 2023-10-17

SRSvsWBRT

Phase 3 Unknown

98 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05755048 2023-09-01

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

314 enrolled

Breast

Breast Neoplasms

NCT05985187 2023-08-14

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase 3 Unknown

412 enrolled

Breast

HER2-positive Breast Cancer

NCT05433480 2023-07-27

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Phase 3 Unknown

274 enrolled

Breast

Breast Neoplasms

NCT01579734 2023-06-28

HOT

Phase 3 Unknown

1,884 enrolled

Breast

Breast Neoplasms

NCT05871918 2023-05-23

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Phase 3 Unknown

832 enrolled

Breast

HER-2 Positive Breast Cancer

NCT03613181 2023-04-24

ANGLeD

Phase 3 Unknown

150 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT05790096 2023-03-29

Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy

Phase 3 Unknown

60 enrolled

Breast

Breast Neoplasms

NCT00412022 2023-03-24

HOBOE

Phase 3 Unknown

1,294 enrolled

Breast

Breast Neoplasms

NCT05753865 2023-03-03

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Phase 3 Unknown

454 enrolled

Breast

Advanced Breast Cancer

NCT05728632 2023-02-23

CONTROL

Phase 3 Unknown

80 enrolled

BreastLymphoid

Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Ventricular Dysfunction, Left, Cardiotoxicity

NCT05637671 2023-02-08

Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms

Phase 3 Unknown

146 enrolled

Breast

Breast Neoplasms, Hot Flashes

NCT02914158 2023-01-17

ASPAIT

Phase 3 Unknown

680 enrolled

Breast

Breast Neoplasms

NCT05670054 2023-01-04

Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

Phase 3 Unknown

116 enrolled

Breast

Breast Neoplasms

NCT03863223 2022-11-23

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

Phase 3 Unknown

590 enrolled

Breast

Breast Neoplasms

NCT00887380 2022-11-18

STARS

Phase 3 Unknown

2,023 enrolled

Breast

Breast Neoplasms

NCT02973737 2022-10-25

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

Phase 3 Unknown

279 enrolled

Breast

HER2 Positive Metastatic Breast Cancer

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Phase 3 Unknown

434 enrolled

Breast

Advanced Breast Cancer

NCT05438810 2022-07-05

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Phase 3 Unknown

312 enrolled

Breast

Advanced Breast Cancer

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

120 enrolled

Breast

HER2+ Breast Cancer

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3 Unknown

240 enrolled

Breast

Breast Neoplasms

NCT01547741 2022-04-14

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Phase 3 Unknown

1,871 enrolled

Breast

Breast Neoplasms

NCT02236806 2022-02-01

SAFE

Phase 3 Unknown

262 enrolled

Breast

Breast Neoplasms, Cardiotoxicity

NCT00212121 2022-01-21

Radiation Dose Intensity Study in Breast Cancer in Young Women

Phase 3 Unknown

2,400 enrolled

Breast

Breast Neoplasms

NCT05164952 2021-12-21

Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

Phase 3 Unknown

50 enrolled

Breast

Breast Neoplasms

NCT05016349 2021-08-23

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Phase 3 Unknown

160 enrolled

Breast

Breast Cancer Female

NCT04047758 2021-07-20

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Phase 3 Unknown

420 enrolled

Breast

Breast Neoplasms

NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

375 enrolled

Breast

Advanced Breast Cancer

NCT03927456 2021-06-03

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 3 Unknown

357 enrolled

Breast

Advanced Breast Cancer

NCT03966898 2021-06-02

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 3 Unknown

426 enrolled

Breast

Advanced Breast Cancer

NCT03980054 2021-05-24

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Phase 3 Unknown

1,192 enrolled

Breast

Breast Neoplasms

NCT04803266 2021-03-17

Elective Internal Mammary Node Irradiation in Women With Node-positive Breast Cancer

Phase 3 Unknown

747 enrolled

Breast

Breast Neoplasms

NCT04665986 2020-12-14

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Phase 3 Unknown

50 enrolled

Breast

Breast Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

474 enrolled

Breast

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

NCT01917279 2020-07-23

CAMELLIA

Phase 3 Unknown

280 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Skin Diseases

NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Phase 3 Unknown

240 enrolled

Breast

HER2 Positive Metastatic Breast Cancer

NCT04403529 2020-06-01

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Phase 3 Unknown

200 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 3 Unknown

332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Phase 3 Unknown

338 enrolled

Breast

HER2-positive Metastatic Breast Cancer

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Phase 3 Unknown

290 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase 3 Unknown

316 enrolled

Breast

Breast Neoplasms

NCT01758146 2020-03-04

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

Phase 3 Unknown

412 enrolled

BreastOther

Breast Neoplasms, Obesity

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Phase 3 Unknown

3,697 enrolled

Breast

Breast Neoplasms

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Phase 3 Unknown

410 enrolled

Breast

HER2-positive Advanced Breast Cancer